癌症研究
伦瓦提尼
肝细胞癌
癌基因
肿瘤微环境
趋化因子
生物
CD8型
渗透(HVAC)
免疫疗法
医学
免疫
癌变
免疫系统
六氯环己烷
信号转导
免疫学
突变
外周血单个核细胞
突变体
化学
抑制器
作者
Fei Zhao,Kun Chen,Yiqiao Deng,Shaoyan Cheng,Chentong Xiao,Yi Yang,Junbo Liang,Haizhen Lu,Xu Che,C Xu,Xing-Ning Li,Zhiyuan Wu,Jianqiang Cai,Hongying Wang,Wei Song,Chunfeng Qu,Hong Zhao
标识
DOI:10.1038/s41419-026-09326-4
摘要
Hepatocellular carcinoma (HCC) patients frequently fail to respond to combined anti-PD1 immunotherapy, though pre-existing neoantigen-specific CD8⁺ T cells within tumor microenvironment are reinvigorated upon PD1 blockaded. Tumor-intrinsic mechanisms driving the therapeutic resistance in HCC remain unclear. Here, we analyzed pretreatment tumor biopsies from 78 advanced HCC patients receiving lenvatinib plus anti-PD1, and found that activation of Wnt/β-catenin signaling was significantly enriched in non-responders (49/78) compared with responders (29/78). Further analyses in 114 NCC-HCCs and 358 TCGA-LIHCs, a paucity of CD4⁺ T cells and mononuclear phagocytes was detected specifically in tumors harboring CTNNB1 mutations affecting the β-TrCP binding motif, particularly D32 mutations, but not in tumors with other Wnt/β-catenin activating alterations. We constructed β-catenin mutants at D32 (D32-mutant), transducing SK-Hep1 HCC cells and inducing murine liver cancers via hydrodynamic tail-vein injection of oncogene vector mixtures. D32-mutant strongly suppressed HCC cell-intrinsic NF-κB activity to repress the production of multiple chemokines and inflammatory cytokines, demoting CD4 + T-cell-mediated antitumor immunity by restraining mononuclear phagocyte infiltration and maturation. In C57BL/6 mice bearing SC4.D32 tumor, deficient in MHC-I mediated CD8 + T-cell-recognition, E7386 addition improved anti-PD1 antitumor effect and augmented lenvatinib plus anti-PD1 efficacy, relating to the enhancement of CD4 + T-cell-mediated antitumor immunity by recovering tumor-intrinsic NF-κB activity to increase tumor infiltration of phagocytes and their communication with CD4⁺ T cells. Thus, potentiating tumor-intrinsic NF-κB activity in mutated CTNNB1 -driven “immune excluded” HCCs could advance anti-PD1 treatment efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI